Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Dragan Jovanovic is active.

Publication


Featured researches published by Dragan Jovanovic.


Therapeutic Apheresis and Dialysis | 2007

Effects of Lowering Dialysate Calcium Concentration on Mineral Metabolism and Parathyroid Hormone Secretion: A Multicentric Study

Visnja Lezaic; Svetlana Pejanovic; Sveta Kostic; Stevo Pljesa; Nada Dimkovic; Ljiljana Komadina; Dragan Jovanovic; Jelena Marinkovic; Ljubica Djukanovic

Abstract:  This prospective study was conducted with the aim of examining the efficacy of lowering dialysate calcium (dCa) in order to: (i) stimulate bone turnover in hemodialysis patients with biochemical signs of adynamic bone disease (ABD) (hypercalcemia, normal alkaline phosphatase and intact parathyroid hormone (iPTH) <150 pg/mL); and (ii) diminish hypercalcemia in patients with secondary hyperparathyroidism (sHPT) (hypercalcemia, high alkaline phosphatase and iPTH > 400 pg/mL), thus permitting the use of calcium‐containing phosphorus binders and vitamin D metabolites. Patients were divided into: an ABD–treated group (24 patients), a sHPT–treated group (18 patients), an ABD–control group (12 patients) and a sHPT–control group (11 patients). For the ABD‐ and sHPT–treated patients, hemodialysis was conducted with dCa 1.5 mmol/L for three months and then with dCa 1.25 mmol/L for an additional three months, while in the control groups hemodialysis was conducted with dCa 1.75 mmol/L during the entire study. Reduction of dCa in patients with ABD caused a slight but insignificant decrease of Ca, but a significant and permanent increase of bone‐specific alkaline phosphatase and intact parathyroid hormone level serum levels. Reduction of dCa in patients with sHPT slightly but insignificantly decreased Ca and intact parathyroid hormone level values. Nevertheless, this enabled the calcium‐based phosphate binder dose to be raised and vitamin D3 metabolites to be introduced. Logistic regression analysis indicated that milder bone disease (both ABD and sHPT) was associated with more the favorable effect of dCa reduction. Thus, low dCa stimulated parathyroid glands and increased bone turnover in ABD patients, and enabled better control of mineral metabolism in sHPT patients.


Nephron Clinical Practice | 2009

Mycophenolate Mofetil in High-Risk Patients with Primary Glomerulonephritis: Results of a 1-Year Prospective Study

Nada Dimkovic; Dragan Jovanovic; Zoran Kovacevic; Violeta Rabrenovic; Vidosava Nesic; Marina Savin; Branka Mitić; Marina Ratkovic; Slobodan Curic; Igor Mitic; Steva Pljesa; Gordana Perunicic-Pekovic; Jelena Marinkovic; Jovan Popovic; Danica Vujic

Background/Aims: Glucocorticoids and classic immunosuppressive drugs can improve disease activity in primary glomerulonephritis (GN). However, these drugs have serious toxicity and patients frequently experience inadequate response or relapse, so there is a need for alternative agents. This multicenter uncontrolled study analyzed the efficacy and safety of mycophenolate mofetil (MMF) in high-risk patients with primary GN. Methods: A total of 51 patients with biopsy-proven membranous (n = 12), membranoproliferative (n = 15), mesangioproliferative (n = 10), focal segmental glomerulosclerosis (n = 13) and minimal change disease (n = 1) received MMF with low-dose corticosteroids for 1 year. The primary outcome included the number of patients with complete/partial remission. Results: Proteinuria significantly decreased, from its median value of 4.9 g/day (IQR 2.9–8.4) to 1.28 g/day (IQR 0.5–2.9), p < 0.001. The urine protein/creatinine ratio significantly improved, from a median of 3.72 (IQR 2.13–6.48) to 0.84 (IQR 0.42–2.01), p < 0.001. The mean area under the curve for proteinuria significantly decreased, from 4.99 ± 3.46 to 2.16 ± 2.46, between the first (visits 1–2) and last (vists 4–5) treatment periods (p < 0.001). The change was similar for every type of GN, without difference between groups. eGFR slightly increased (62.1 ± 31.8 to 65.3 ± 31.8 ml/min, p = n.s.) and ESR, total proteins, albumins, total- and HDL-cholesterol parameters improved significantly. Systolic, diastolic and mean blood pressure decreased (p < 0.02 for systolic blood pressure). The age of patients was the only independent predictor of complete or partial remission. Conclusion: MMF proved to be efficient in 70% of high-risk patients with primary GN, who reached either complete or partial remission without safety concern after 12 months of treatment. Favorable effects of MMF therapy have to be confirmed in the long term and particularly after discontinuation of the drug.


Kidney & Blood Pressure Research | 2010

Treatment of Lupus Nephritis by Mycophenolate Mofetil

Violeta Rabrenovic; Mileta Poskurica; Zoran Kovacevic; Vidosava Nesic; Marina Savin; Branka Mitić; Nada Dimkovic; Čedomir Čučković; Danica Vujic; Steva Pljesa; Gordana Perunicic-Pekovic; Slobodan Curic; Igor Mitic; Marina Ratkovic; Jelena Marinkovic; Dragan Jovanovic

Background/Aims: Mycophenolate mofetil (MMF) has been increasingly used for the treatment of lupus nephritis (LN). The aim of this study was to examine the efficacy and safety of MMF used with low doses of corticosteroids as maintenance therapy in patients with LN. Methods: The study covered 35 patients, most of them with proliferative types of LN (5 WHO class III, 26 class IV), while 1 had class V and 3 class VI nephritis. MMF was administered in the dose of 1.5–2 g/24 h and prednisone at 10–20 mg/day. The treatment effects were followed over a 12-month period. Results: After 3 months of therapy significant reduction in proteinuria was achieved (2.1 ± 2.4 g/24 h vs. 1.0 ± 1.0 g/24 h, p < 0.01) and maintained to the end of the study. In parallel, a significant rise in serum albumin, a fall of cholesterol and a significant increase in mean glomerular filtration rate were noted. Complete remission was achieved in 16 patients (45.7%), including all patients in class III and V plus 10 patients in class IV. Not a single adverse effect was observed. Conclusion: MMF combined with low doses of steroids is an effective and safe treatment for the maintenance of stable remission of LN.


Vojnosanitetski Pregled | 2009

Our first experiences in applying an original method for removal of ABO-isoagglutinins in ABO-incompatible kidney recipients

Ljiljana Ignjatovic; Zoran Kovacevic; Dragan Jovanovic; Neven Vavic; Zoran Paunic; Milorad Radojevic; Violeta Rabrenovic; Katarina Obrencevic; Mirjana Mijuskovic; Biljana Draskovic-Pavlovic; Gordana Ostojic; Bela Balint; Dubravko Bokonjic

BACKGROUND/AIM Due to improved methods for removal of ABO isoagglutinins and novel immunosuppressive protocols, short and long-term outcome in blood group incompatible is similar to blood group compatible kidney transplantation. The aim of this study was to determine the efficacy of our original method for removal of ABO isoagglutinins from the blood in ABO-incompatible kidney allograft recipients. METHOD Between 2006 and 2008 twelve patients were transplanted from ABO incompatible living donors. Titers of ABO isoagglutinins were 4-128 (IgG). Immunosuppressive therapy started 14 days before kidney transplantation with rituximab, followed by a triple therapy (prednisone + tacrolimus + mycophenolate mofetil) and the first plasma exchange (PE) procedure, in which one plasma volume was substituted with albumin and saline on day 7 before transplantation. For selective extracorporeal immunoadsorption, the removed plasma was mixed with donor blood type filtered red blood cells, centrifuged and the supernatant separated and preserved. In the next PE procedure, the removed plasma was replaced with immunoadsorbed plasma, and so on. Titers of ABO agglutinins, renal allograft function and survival were followed-up. RESULTS The pre-transplant treatment consisting of 1-5 PE procedures and immunosuppressive therapy resulted in target ABO agglutinins titers below 4. During a 10-24 month follow-up three patients had an early acute rejection, one patient acute rejection and hemolytic anemia, two patients surgical complications and one of them lost his graft. In the post-transplant period, the titers of ABO antibodies remained below 4. All the patients had stable kidney allograft function with mean serum creatinine +/- SD of 129 +/- 45 micromol/l at the end of the study. CONCLUSION Our method for removal of ABO antibodies was effective in a limited series of patients and short-term follow-up.


Vojnosanitetski Pregled | 2007

[Mycophenolate mofetil combined with steroids: new experiences in the treatment of idiopathic retroperitoneal fibrosis].

Katarina Obrencevic; Dragan Jovanovic; Zoran Kovacevic; Rajko Hrvacevic; Ljiljana Ignjatovic; Mirjana Mijuskovic

BACKGROUND/AIM [corrected] Idiopathic retroperitoneal fibrosis (IRF) is an uncommon disease characterized by a retroperitoneal fibrotic tissue that often involve the ureters, leading to the obstructive nephropathy and variable impairment of renal function. Findings strongly suggest an autoimmune etiology. Surgery, medical treatment with immunosuppressive drugs, or a combination of both are proposed. The optimal treatment has not been established yet. The aim of this study was to present our experience with combined immunosuppressive therapy of IRF, steroids (S) and mycophenolate mofetil (MMF). METHODS We prospectively followed four patients with IRF from January 2004 to December 2006. Three patients had an active disease with bilateral hydronephrosis. In the two of them acute renal failure was presented, and ureteral catheters were inserted in one in order to manage ureteral obstruction. One patient has came to our unit with a relapse of IRF and incipient chronic renal failure after the prior therapy with ureterolysis and immunosuppressive drugs (azathioprine and tamoxifen). All patients received steroids and MMF. Two patients were treated with intravenous methylprednisolone pulses (250 mg each), for three consecutive days, followed by oral prednisone 0.5 mg/kg/day. The other two patients received oral prednisone at the same dose. Prednisone was gradually tappered to a maintenance dose of 10 mg/kg/day. Simultaneously, all patients received MMF, initially 1 g/day with the increase to 2 g/day. RESULTS After four weeks of the therapy all symptoms disappeared, as well as a hydronephrosis with a decrease of erythrocyte sedimentation rate and Creactive protein (CRP) to normal level in all patients. Three patents remain in remission untill the end of the follow up. One patient had a relapse because of stopping taking the therapy after six months. He was treated by oral prednisone 0.5 mg/kg/day, which was gradually decreased. After twelve weeks hydronephrosis disappeared and CRP returns to the normal level. CONCLUSION The combination of steroids and mycophenolate mofetil led to the remission of IRF with a strong and quick immunosuppressive effect. It also provided avoiding the long-term use of high steroid dose and surgical procedures.


Vojnosanitetski Pregled | 2006

[Extramedular plasmacytoma in the urinary bladder--unusual localization].

Violeta Rabrenovic; Zoran Kovacevic; Dragan Jovanovic; Milorad Rabrenovic; Novak Milovic; Snežana Cerović

BACKGROUND Multiple myeloma is a plasmaproliferative disease characterized by the uncontrolled proliferation of a pathogenic plasma cell clone engaged in the production of monoclonal immunoglobulin. This condition affects the bone marrow, but it can be manifested in any other organ or tissue. The urinary bladder involvement is extremely rare. CASE REPORT We reported a 70-year-old male with the history of multiple myeloma, receiving chemotherapy containing melphalan and prednisone (MP). Two years after the treatment, there was a renal failure associated with oligoanuria, hematuria and bilateral hydronephrosis. The urine cytology tests revealed the atypical cells, so was suspected obstructive uropathy to be caused by urothelium cancer. However, only upon the cystoscopy and biopsy performed on the urinary bladder mass, plasmacytoid infiltration diagnosis was confirmed. This extremely rare variant was presented throughout the illness period and proved to be resistant to the administered chemotherapy. CONCLUSION When renal failure associated with hematuria and bilateral hydronephrosis is presented in a patient with multiple myeloma, this unusual and rare extramedular localization should be also considered.


Vojnosanitetski Pregled | 2009

Anterior pituitary lobe atrophy as late complication of hemorrhagic fever with renal syndrome

Dragan Jovanovic; Zoran Kovacevic; Tamara Dragovic; Marijana Petrovic; Jelena Tadic

INTRODUCTION Hemorrhagic fever with renal syndrome (HFRS) is acute infective multisystemic disease followed by febrility, hemorrhages and acute renal insufficiency. Bleeding in the anterior pituitary lobe leading to tissue necrosis occurs in acute stage of severe clinical forms of HFRS, while atrophy of the anterior pituitary lobe with diminution of the gland function occurs after recovery stage. CASE REPORT We presented a patient with the development of chronic renal insufficiency and hypopituitarism as complication that had been diagnosed six years after Hantavirus infection. Magnetic resonance of the pituitary gland revealed atrophy and empty sella turcica. CONCLUSION Regarding frequency of this viral infection and its endemic character in some parts of our country partial and/or complete loss of pituitary function should be considered during the late stage of HFRS.


International Urology and Nephrology | 2017

Erratum to: Vascular access registry of Serbia: a 4-year experience

Tamara Jemcov; Nada Dimkovic; Dragan Jovanovic; Tanja Lazarevic; Igor Mitic; Radomir Naumovic; Sanja Simic-Ogrizovic; Radmila Velickovic

Nasta, Jelacic Rosa, Kostic Mirjana, Kovacevic Miodrag, Lazarevic Tatjana, Markovic Rodoljub, Micunovic Vesna, Milenkovic Olgica, Milenkovic Radomir, Milenkovic Srboljub, Milicevic Biserka, Milicevic Olivera, Nikolic Zora, Obrenovic Slavica, Orescanin Mira, Pavlovic Stevan, Pesic Snezana, Petkovic Dobrila, Pilipovic Dragana, Prokopovic Miomir, Radovanovic Zoran, Rakic Nenad, Rangelov Vanja, Sefer Kornelija, Sibalic Simin Marija, Stefanovic Nikola, Stojanovic Dragoslav, Stojanovic Stanojevic Marina, Tirmenstajn Jankovic Biserka, Vasic Jovanovic Vesna, Vasilic Kokotovic Olivera, Vojinovic Goran, Vuckovic Dragana, Vukelic Vesna, Vukic Jasmina, Zagorac Nikola, Zec Nenad. Erratum to: Int Urol Nephrol DOI 10.1007/s11255‐016‐1378‐9


Vojnosanitetski Pregled | 2015

Kidney failure as an unusual initial presentation of biclonal gammopathy (IgD multiple myeloma associated with light chain disease)--a case report.

Violeta Rabrenovic; Zoran Mijuskovic; Slobodan Marjanovic; Milorad Rabrenovic; Dragan Jovanovic; Svetlana Antić; Ljiljana Ignjatovic; Milica Petrovic; Dejan Pilcevic

INTRODUCTION Immunoglobulin D (IgD) myeloma is a rare disease, about 2% of all myelomas, even rarer when accompanied with another multiple myeloma in biclonal gammopathy. We presented a case of biclonal gammopathy-as-sociated manifestation of IgD myeloma and light chain disease in a patient who initially had renal failure. CASE REPORT 37-year-old male approximately one month before hospitalization began to feel malaise and fatigue along with decreased urination. Laboratory analysis revealed azotemia. A dialysis catheter was placed and hemodialysis started. The patient was then admitted to our hospital for further tests and during admission, objective examination revealed pronounced paleness with hepatosplenomegaly and hypertension (170/95 mmHg). Laboratory analysis showed erythrocyte sedimentation rate 122 mm/h, expressed anemic syndrome (Hb 71 g/L) and renal failure dialysis rank: creatinine 1,408 micromol/L, urea 31.7 mmol/L. There was two M components in serum protein electrophoresis: IgD lambda and free light chain lambda. Proteinuria was nephrotic rank (5.4 g/24 h), whose electrophoresis revealed 2 M components--massive in alpha 2 fraction of 71%; 7% in the discrete beta fraction, beta 2M / serum 110 mg / L, in urine 1.8 mg/L--extremely high; IgL kappa I lambda index 1:13 (reference value ratio 2:1). The findings pointed to double myeloma disease: IgD myeloma and Bence Jones lambda myeloma. Bone biopsy confirmed IgD myeloma lambda 100% infiltration medulla predominantly plasmablasts. The treatment continued with hemodialysis 3 times per week with chemotherapy protocol bortezomib, doxorubicin, dexamethasone. After 4 cycles of chemotherapy, there was a decrease of IgD, lamda-light chains, reduction in proteinuria (1.03 g/24 h), so hemodialysis was reduced to once per week. Six months after treatment initiation the patient underwent autologous bone marrow transplantation. In a 2-year follow-up period double myeloma disease showed complete remission. CONCLUSION The presented rare form of double myeloma disease with initial renal insufficiency underscores the importance of careful observation and teamwork that can alter the course of this serious disease.


The Journal of Infectious Diseases | 1992

Belgrade Virus: A New Hantavirus Causing Severe Hemorrhagic Fever with Renal Syndrome in Yugoslavia

Ana Gligic; Nada Dimkovic; Shu-Yuan Xiao; Guy J. Buckle; Dragan Jovanovic; Dragisa Velimirovic; Radivoj Stojanovic; Mirceta Obradovic; Gordana Diglisic; Jasmina Micic; David M. Asher; James W. LeDuc; Richard Yanagihara; D. Carleton Gajdusek

Collaboration


Dive into the Dragan Jovanovic's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Djoko Maksic

Military Medical Academy

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Neven Vavic

Military Medical Academy

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge